NF2 and cancer: Given that loss-of-function mutations and reduced NF2 expression are frequently observed in human cancer [7], it is interesting to speculate that the CRL4DCAF1-LATS axis might be a potential target for cancer treatment, especially for a subset of patients with NF2 lesions.